Mallinckrodt has expanded its agreement with group purchasing organization Premier, adding new products and extending their existing contract by two years. New Mallinckrodt technologies and products added to the partnership include Nellcor pulse
Mallinckrodt has expanded its agreement with group purchasing organization Premier, adding new products and extending their existing contract by two years. New Mallinckrodt technologies and products added to the partnership include Nellcor pulse oximeters and sensors, Liebel-Flarsheim power injector disposables, and the Optison ultrasound contrast agent (developed by San Diego-based Molecular Biosystems).
The earlier agreement between Premier and Mallinckrodt covered other Mallinckrodt contrast imaging agents, radiopharmaceuticals and related products, endotracheal tubes, tracheostomy tubes, and temperature monitoring systems. All of those items will remain under the new expanded agreement, which will conclude at the end of 2006, according to St. Louis-based Mallinckrodt.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.